Alnylam CSO sells 1,291 shares in planned trades
Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Joseph Fitzgerald reported open-market sales of company stock.
Rhea-AI Filing Summary
Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Joseph Fitzgerald reported open-market sales of company stock. On March 4–5, 2026, he sold a total of 1,291 shares of common stock in multiple transactions at prices generally in the low $320 range.
Footnotes state that some shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding on vested restricted stock units, and that the transactions were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025. After these sales, Fitzgerald directly owns 20,569 common shares and indirectly holds 537 shares through a managed account associated with the company’s 401(k) matching program.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 124 | $321.81 | $40K |
| Sale | Common Stock | 233 | $323.25 | $75K |
| Sale | Common Stock | 148 | $324.60 | $48K |
| Sale | Common Stock | 153 | $326.24 | $50K |
| Sale | Common Stock | 29 | $319.03 | $9K |
| Sale | Common Stock | 28 | $320.01 | $9K |
| Sale | Common Stock | 59 | $320.81 | $19K |
| Sale | Common Stock | 79 | $321.82 | $25K |
| Sale | Common Stock | 96 | $323.01 | $31K |
| Sale | Common Stock | 210 | $323.84 | $68K |
| Sale | Common Stock | 75 | $324.88 | $24K |
| Sale | Common Stock | 57 | $325.67 | $19K |
| holding | Common Stock | -- | -- | -- |
Footnotes (15)
- F1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
- F2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F10. This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.
- F11. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F12. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F13. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F14. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F15. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
AI-generated analysis. How Rhea-AI works. Not financial advice.